Creative Biolabs Announces a Satisfactory Result in Its Research Cooperation with In-Cell-Art

SHIRLEY, NY, USA - Oct 27, 2016 - Creative Biolabs, a biotech company specialized in providing custom biotechnology and pharmaceutical services that cover the full scope of biotechnology needs, announces that its services provided to In-Cell-Art (ICA) lead to a satisfactory result in the research collaboration between ICA and Virbac.

Creative Biolabs helped In-Cell-Art (ICA) in successfully completing a research service for Virbac, a global independent pharmaceutical company dedicated to animal health, with the aim of discovering unique antibodies via Nanotaxi® formulated DNA immunizations against a confidential target as part of Virbac’s in vitro programme.

In this collaboration, ICA took in charge of the monoclonal antibody discovery work starting from DNA sequence optimization, then DNA synthesis, subcloning to ICA’s proprietary plasmid, amplification, purification, quality control, Nanotaxi® production and formulation, and immunizations in chosen species of animals. The figure below is the schematic presentation of this antibody discovery program by ICA (“ICANTibodies™”).

With the immunizations been successfully completed by ICA, extracted RNA was sent to Creative Biolabs. It provided services for ICA in phage display library construction and biopanning, single clone validation, DNA sequencing and quality control in monoclonal format for the discovery of monoclonal antibodies.

“These series of services by Creative Biolabs yielded a satisfactory number of monoclonal antibodies specific to the target for further evaluation at Virbac”, says Bruno Pitard, head of Scientific Advisory Board and co-founder of In-Cell-Art.

Dong H. Chen, Chief Scientific Officer of Creative Biolabs says that “this is a good example to demonstrate the power of combining ICA’s Nanotaxi®/DNA immunization and Creative Biolabs’ Magic™ Antibody Discovery Platform which allows us to  provide one-stop service for our customers to discover unique monoclonal antibodies with high specificity and affinity to their targets”.

Its Native™ Antibody Discovery Platform is based on single cell sorting, allowing the discovery of high-affinity native monoclonal antibodies with all major antibody gene clusters from plasma and memory B cells of a wide range of species including rabbit and monkey.

For antigens that do not have immune response in animals or cannot be applied in animals, Creative Biolabs can screen multiple premade naïve and synthetic libraries. It has years of experience in raising functional monoclonal antibodies against multiple-pass membrane proteins.

“Although backed up by Nanotaxi®, we couldn’t make this collaboration a complete one without the final processes by Creative Biolabs”.

About Creative Biolabs

Creative Biolabs is a professional service provider in developing highly specific, high affinity monoclonal antibodies from all popular antibody production species, including rabbit, chicken, llama, camel, alpaca, cow, dog, mouse, rat, sheep, monkey, human, and most recently shark. It is also specialized in providing custom biotechnology and pharmaceutical services that cover the full scope of biotechnology needs of early antibody drug discovery and development.